このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors (GD2CART-BEV)

2026年10月29日 更新者:Universität Münster

A Phase Ib Safety, Dose Finding and Feasibility Trial of GD2IL18CART Combined With Bevacizumab in Patients With Relapsed or Refractory GD2 Positive Solid Cancers

This study will test a chimeric antigen receptor (CAR) T-cell treatment combined with bevacizumab in children and young adults with relapsed or refractory neuroblastoma, Ewing sarcoma, or osteosarcoma.

The CAR T-cell treatment, called GD2IL18CART, is made from a patient's own T cells. The T cells are genetically modified to recognize GD2, a molecule found on the surface of these cancers, and to release the immune-stimulating protein interleukin-18 (IL-18) when they encounter tumor cells. Bevacizumab is an antibody that blocks vascular endothelial growth factor (VEGF), a protein that affects tumor blood vessels and may make it difficult for immune cells to enter tumors. Combining bevacizumab with GD2IL18CART may therefore help more CAR T cells reach the tumor and improve their antitumor activity.

The main goals of this study are to determine whether the combination can be given safely, identify a recommended dose of GD2IL18CART for use with bevacizumab, and look for early evidence of antitumor activity. The study will also examine blood and tumor samples to better understand how the treatment affects CAR T cells and the tumor environment.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This is an international, prospective, multicenter, open-label, non-randomized phase Ib dose-escalation and dose-expansion study evaluating GD2IL18CART in combination with bevacizumab in children, adolescents, and young adults with relapsed or refractory GD2-positive neuroblastoma, Ewing sarcoma, or osteosarcoma.

GD2IL18CART is an autologous chimeric antigen receptor (CAR) T-cell product directed against the tumor-associated antigen GD2 and engineered for antigen-inducible secretion of interleukin-18 (IL-18). Clinical investigation of GD2IL18CART as a single agent demonstrated robust CAR T-cell expansion and established doses that could be administered with a manageable safety profile. However, clinical activity remained limited, particularly at non-osseous tumor sites and in Ewing sarcoma and osteosarcoma.

The combination with bevacizumab is intended to address tumor microenvironmental barriers that may limit CAR T-cell access and activity. Bevacizumab is a monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGF-A). Persistent VEGF signaling contributes to abnormal tumor vasculature that can restrict immune-cell trafficking and promote local immunosuppression. In preclinical models of Ewing sarcoma and neuroblastoma, vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) pathway inhibition increased intratumoral accumulation and antitumor activity of GD2-directed CAR T cells. Bevacizumab also enhanced the antitumor activity of the clinical GD2IL18CART product. These findings provide the rationale for evaluating the combination clinically.

Following leukapheresis and manufacture of the autologous GD2IL18CART product, participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide on days -6 to -4. Bevacizumab will be administered intravenously at 15 mg/kg on day -3, followed by a single intravenous infusion of GD2IL18CART on day 0. Additional bevacizumab doses will be administered every 3 weeks for up to five doses in total, unless treatment is discontinued earlier according to protocol-defined criteria. The timing of bevacizumab is intended to initiate VEGF inhibition before CAR T-cell infusion and maintain VEGF inhibition during the early period of CAR T-cell trafficking, expansion, and persistence.

GD2IL18CART dose escalation will follow a cohort-based single ascending dose design. The starting dose is lower than the doses established during previous clinical investigation of GD2IL18CART as a single agent because bevacizumab may increase tumor infiltration and biological activity of the CAR T cells. Cohorts of three participants will be treated sequentially, with predefined stopping rules and independent Data Monitoring Committee review guiding dose escalation. The objective of the dose-escalation phase is to characterize the safety of the combination and determine a recommended GD2IL18CART dose for use with bevacizumab.

After determination of the recommended combination dose, disease-specific expansion cohorts will enroll participants with neuroblastoma, Ewing sarcoma, and osteosarcoma, with up to six participants per disease entity treated at the recommended dose. The expansion phase will further characterize safety, feasibility, biological activity, and preliminary antitumor activity of the combination.

Tumor response will be assessed at weeks 6 and 12 and at months 6 and 12. Participants will be followed within this study through month 12. Long-term follow-up after genetically modified cell therapy will continue for up to 15 years in a separate long-term follow-up study.

An integrated translational research program will investigate the biological effects of the combination. Longitudinal analysis of blood samples will assess CAR T-cell expansion, persistence, phenotype, and immune responses. Mandatory on-treatment tumor biopsies obtained on day 14 will be analyzed using molecular and spatial approaches to investigate CAR T-cell trafficking and function within the tumor microenvironment and to identify potential biological determinants of response and resistance.

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • North Rhine-Westphalia
      • Münster、North Rhine-Westphalia、ドイツ、48149
        • Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年~25年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Participants must have relapsed and/or refractory neuroblastoma, osteosarcoma, or Ewing sarcoma judged to be incurable with conventional treatment and meet the following disease-specific requirements:

    • Neuroblastoma: Patients with locoregional recurrence must have received surgery and/or radiotherapy followed by relapse chemotherapy. Patients with metastatic recurrence after initial classification as intermediate risk must have received high-risk therapy. Patients with recurrence after initial classification as high risk must have received relapse chemotherapy alone or combined with immunotherapy.
    • Osteosarcoma: Patients must have received frontline therapy and at least one prior line of relapse systemic anticancer therapy for relapsed or refractory disease. Patients with an isolated relapse manifestation (lung metastasis or local relapse) must have unresectable disease.
    • Ewing sarcoma: Patients must have received frontline therapy and at least one prior line of relapse chemotherapy according to standard regimens. Patients with an isolated lung relapse must have received pulmonary irradiation during frontline or relapse therapy.
  • All participants must additionally meet the following criteria:

    • GD2 expression on tumor cells in an archival biopsy assessed by the central reference laboratory. GD2-positive tumor is defined as GD2 at least 50% of tumor cells expressing GD2 at an intensity of 2+ or higher, using an immunofluorescence assay for specific detection of GD2 expression in formalin-fixed, paraffin-embedded or frozen tumor tissue with semiquantitative evaluation.
    • Evaluable disease based on Response Evaluation Criteria in Solid Tumors for all disease entities or, in cases of diffuse bone/bone marrow metastases, by whole-body nuclear medicine imaging (e.g. metaiodobenzylguanidine (MIBG)) scan for neuroblastoma or positron emission tomography (PET) based imaging.
    • Age ≥1 year and ≤25 years.
    • Absolute cluster of differentiation 3 (CD3)-positive T-cell count ≥200/µL.
    • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 for participants >16 years of age or Lansky performance score ≥60 for participants ≤16 years of age at screening.
    • No childbearing potential, or negative pregnancy test at screening and before chemotherapy in participants with childbearing potential.
    • Signed and dated informed consent/assent by participants and/or their caregivers before any trial-specific procedure.

Exclusion Criteria:

  • Active solid central nervous system (CNS) metastases or metabolically active metastatic disease in the skull with direct contact to the dura.

  • Current autoimmune disease or history of autoimmune disease with potential CNS involvement.

  • Active clinically significant CNS dysfunction, including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, or paralysis.

  • History of an additional malignancy other than non-melanoma skin cancer or carcinoma in situ unless disease-free for ≥3 years.

  • Pre-existing severe lung disease, oxygen requirement of >28% inspired oxygen (O2) supplementation, or active pulmonary infiltrates on X-ray.

  • Cardiac function: Pediatric patients (˂18 yrs): fractional shortening <28% or left ventricular ejection fraction <50% by echocardiography, young adult patients (18-25 yrs): left ventricular ejection fraction <50% by echocardiography.

  • Renal function: GFR ≤29 mL/min/1.73 m22 by CKD-EPI for patients ≥18 yrs or creatinine clearance ≤29 mL/min/1.73 m2 by Schwartz formula for patients <18 yrs of age.

  • Liver function: serum bilirubin >3 times the upper limit of normal (ULN) or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >5 times ULN, unless attributable to liver infiltration by the underlying malignant disease.

  • Hematological function: absolute neutrophil count (ANC) <500/µL or platelet count <50 × 10³/µL.

  • Presence of any active infection.

  • Bevacizumab-specific exclusion criteria:

    • uncontrolled arterial hypertension, history of hypertensive crisis or hypertensive encephalopathy,
    • clinically significant proteinuria.
    • history of gastrointestinal perforation or clinically significant fistula, or current condition considered to confer a clinically relevant increased risk of gastrointestinal perforation,
    • clinically significant bleeding or coagulopathy, including recent clinically significant hemoptysis or pulmonary hemorrhage,
    • any history of clinically significant arterial thromboembolic event, including myocardial infarction, cerebrovascular accident, transient ischemic attack, or arterial thrombosis/embolism,
    • clinically significant venous thromboembolism within 6 months before the first dose of bevacizumab,
    • history of posterior reversible encephalopathy syndrome (PRES),
    • clinically significant cardiovascular disease beyond inadequate left ventricular ejection fraction, e.g., uncontrolled arrhythmia, congestive heart failure, unstable angina.
  • Rapidly progressive disease that in the estimation of the Investigator would compromise ability to complete study therapy.

  • Pregnant or breast-feeding females.

  • Concurrent or recent prior therapies:

    • High-dose chemotherapy with autologous stem cell transplantation or requiring autologous stem cell rescue or anticancer biologicals (e.g. mifamurtide) or radiation therapy or major surgery within 30 days prior to leukapheresis.
    • CAR T cells within 3 months before leukapheresis.
    • Checkpoint inhibitors within less than 2 half lives prior to apheresis.
    • Neuroblastoma patients who have relapsed after allogeneic or haploidentical stem cell transplantation must be at least 100 days posttransplant, with no evidence of GVHD and not taking immunosuppressive agents for at least 30 days prior to leukapheresis.
    • I-131 MIBG therapy (neuroblastoma) or other targeted radionuclide therapy must be completed at least 3 months prior to apheresis.
    • GD2-specific antibody therapy with dinutuximab beta or naxitamab within 40 days (5 half-lives) before apheresis.
    • Antiproliferative chemotherapy, epigenetic agents, antibody-drug conjugates, or antibodies targeting antigens other than GD2 within 3 weeks prior apheresis.
    • Immunosuppressive agents other than steroids within 2 weeks before apheresis.
    • Short-acting molecularly targeted agents (kinase inhibitors) within 7 days before apheresis.
    • Systemic corticosteroids, except physiologic replacement dosing, within 7 days before apheresis.
    • Live vaccines within 30 days before apheresis.
  • Hypersensitivity against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy, pre-medication for infusion, rescue medication/salvage therapies for treatment related toxicities.

  • Contraindication to trial related procedures as judged by the Investigator, e.g., tumor biopsy.

  • Female patients of child-bearing potential not willing to practice a highly effective form of birth control from the time of signing the informed consent form and for 12 months after dosing the IMP.

  • Male patients of fathering potential not willing to practice a highly effective form of birth control from the time of signing the informed consent form and for 12 months after dosing the IMP.

  • Concurrent participation in another interventional trial that could interact with this trial, e.g. CAR T trials.

  • Cerebral dysfunction, legal incapacity of adult patients; Committal to an institution on judicial or official order.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:GD2IL18CART + bevacizumab

Participants receive a single intravenous infusion of freshly prepared autologous GD2IL18CART cells in combination with intravenous bevacizumab administered every 3 weeks for up to 5 doses.

Combination of GD2IL1CART (IMP1, EU CT 2022-501725-21-00) with a monoclonal antibody against vascular endothelial growth factor, bevacizumab (IMP2) to promote effective CAR T-cell accumulation and function within the immunosuppressive tumor microenvironment (TME).

他の名前:
  • GD2IL18CART

In combination with GD2IL18CART (IMP1, EU CT 2022-501725-21-00)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence and severity of adverse events
時間枠:Through 12 months after GD2IL18CART infusion

Incidence and severity of adverse events (AEs), graded according to CTCAE version 6.0

Through 12 months after GD2IL18CART infusion
Dose-limiting toxicities and recommended dose - dose-finding part
時間枠:28 days after IMP infusion

Incidence of protocol-defined dose-limiting toxicities (DLTs) and determination of the recommended dose (RD) of GD2IL18CART in combination with bevacizumab using a rule-based small-cohort design

28 days after IMP infusion
Recommended dose of GD2IL18CART in combination with bevacizumab
時間枠:Through completion of the protocol-defined DLT assessment period of 28 days for the final dose-finding cohort

Determination of the recommended dose (RD) of GD2IL18CART in combination with bevacizumab using a rule-based small-cohort dose-escalation design, based on observed dose-limiting toxicities (DLTs) and protocol-defined dose-escalation and stopping rules.

Through completion of the protocol-defined DLT assessment period of 28 days for the final dose-finding cohort
Overall response rate at week 6 - dose-extension part
時間枠:Week 6

Proportion of participants achieving a complete response (CR) or partial response (PR) at week 6

Week 6

二次結果の測定

結果測定
メジャーの説明
時間枠
Intratumoral infiltration of GD2IL18CART
時間枠:Day 14

Presence and extent of GD2IL18CART-cell infiltration in on-treatment tumor biopsies

Day 14
Expansion and persistence of GD2IL18CART
時間枠:From GD2IL18CART infusion through 12 months

Longitudinal assessment of GD2IL18CART-cell expansion, persistence and phenotype in peripheral blood

From GD2IL18CART infusion through 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Claudia Rossig, MD、University Children´s Hospital Münster

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年10月1日

一次修了 (推定)

2031年9月30日

研究の完了 (推定)

2032年12月31日

試験登録日

最初に提出

2026年10月20日

QC基準を満たした最初の提出物

2026年10月20日

最初の投稿 (実際)

2026年10月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年10月29日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • UniMS26_026

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data underlying the published results may be made available to qualified researchers upon reasonable request following publication, subject to applicable informed consent, ethical and data-protection requirements, and execution of an appropriate data-use agreement.

IPD 共有時間枠

Beginning after publication of the primary study results and for a period of 5 years thereafter.

IPD 共有アクセス基準

De-identified individual participant data underlying the published results may be made available to qualified researchers upon reasonable request. Requests will be evaluated based on scientific merit and compatibility with the participants' informed consent, applicable data-protection requirements, and institutional policies. Data will be shared following approval of the request and execution of an appropriate data-use agreement.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。